Selected research
Industry Research
Glucose Dependent Insulinotropic Receptor Industry Research Report 2026
Market perspective
The global Glucose Dependent Insulinotropic Receptor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Glucose Dependent Insulinotropic Receptor market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Glucose Dependent Insulinotropic Receptor market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Glucose Dependent Insulinotropic Receptor market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Glucose Dependent Insulinotropic Receptor include Takeda Pharmaceutical Co Ltd, Novartis AG, Merck & Co Inc, GlaxoSmithKline Plc, Amgen Inc, Yuhan Corp, Taisho Pharmaceutical Holdings Co Ltd, Kowa Co Ltd and Hyundai Pharmaceutical Co Ltd, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Glucose Dependent Insulinotropic Receptor market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Glucose Dependent Insulinotropic Receptor.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Glucose Dependent Insulinotropic Receptor Market by Company
Takeda Pharmaceutical Co Ltd
Novartis AG
Merck & Co Inc
GlaxoSmithKline Plc
Amgen Inc
Yuhan Corp
Taisho Pharmaceutical Holdings Co Ltd
Kowa Co Ltd
Hyundai Pharmaceutical Co Ltd
F. Hoffmann-La Roche Ltd
Dong-A Socio Holdings Co Ltd
CymaBay Therapeutics Inc
Arena Pharmaceuticals Inc
Glucose Dependent Insulinotropic Receptor Segment by Type
MBX-2982
HOB-047
HD-0471953
HD-0471042
GSK-2041706
DA-1241
Others
Glucose Dependent Insulinotropic Receptor Segment by Application
Type 2 Diabetes
Obesity
Chronic Obstructive Pulmonary Disease (COPD)
Dyslipidemia
Others
Glucose Dependent Insulinotropic Receptor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucose Dependent Insulinotropic Receptor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Glucose Dependent Insulinotropic Receptor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucose Dependent Insulinotropic Receptor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Glucose Dependent Insulinotropic Receptor companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- MBX-2982
- HOB-047
- HD-0471953
- HD-0471042
- GSK-2041706
- DA-1241
- Others
Applications
- Type 2 Diabetes
- Obesity
- Chronic Obstructive Pulmonary Disease (COPD)
- Dyslipidemia
- Others
Companies covered
- Takeda Pharmaceutical Co Ltd
- Novartis AG
- Merck & Co Inc
- GlaxoSmithKline Plc
- Amgen Inc
- Yuhan Corp
- Taisho Pharmaceutical Holdings Co Ltd
- Kowa Co Ltd
- Hyundai Pharmaceutical Co Ltd
- F. Hoffmann-La Roche Ltd
- Dong-A Socio Holdings Co Ltd
- CymaBay Therapeutics Inc
- Arena Pharmaceuticals Inc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Glucose Dependent Insulinotropic Receptor by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 MBX-2982
- 2.2.3 HOB-047
- 2.2.4 HD-0471953
- 2.2.5 HD-0471042
- 2.2.6 GSK-2041706
- 2.2.7 DA-1241
- 2.2.8 Others
- 2.3 Glucose Dependent Insulinotropic Receptor by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Type 2 Diabetes
- 2.3.3 Obesity
- 2.3.4 Chronic Obstructive Pulmonary Disease (COPD)
- 2.3.5 Dyslipidemia
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 Glucose Dependent Insulinotropic Receptor Breakdown Data by Type
- 3.1 Global Glucose Dependent Insulinotropic Receptor Historic Market Size by Type (2021-2026)
- 3.2 Global Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Type (2027-2032)
4 Glucose Dependent Insulinotropic Receptor Breakdown Data by Application
- 4.1 Global Glucose Dependent Insulinotropic Receptor Historic Market Size by Application (2021-2026)
- 4.2 Global Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Glucose Dependent Insulinotropic Receptor Market Perspective (2021-2032)
- 5.2 Global Glucose Dependent Insulinotropic Receptor Growth Trends by Region
- 5.2.1 Global Glucose Dependent Insulinotropic Receptor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Glucose Dependent Insulinotropic Receptor Historic Market Size by Region (2021-2026)
- 5.2.3 Glucose Dependent Insulinotropic Receptor Forecasted Market Size by Region (2027-2032)
- 5.3 Glucose Dependent Insulinotropic Receptor Market Dynamics
- 5.3.1 Glucose Dependent Insulinotropic Receptor Industry Trends
- 5.3.2 Glucose Dependent Insulinotropic Receptor Market Drivers
- 5.3.3 Glucose Dependent Insulinotropic Receptor Market Challenges
- 5.3.4 Glucose Dependent Insulinotropic Receptor Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Glucose Dependent Insulinotropic Receptor Players by Revenue
- 6.1.1 Global Top Glucose Dependent Insulinotropic Receptor Players by Revenue (2021-2026)
- 6.1.2 Global Glucose Dependent Insulinotropic Receptor Revenue Market Share by Players (2021-2026)
- 6.2 Global Glucose Dependent Insulinotropic Receptor Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Glucose Dependent Insulinotropic Receptor Head Office and Area Served
- 6.4 Global Glucose Dependent Insulinotropic Receptor Players, Product Type & Application
- 6.5 Global Glucose Dependent Insulinotropic Receptor Manufacturers Established Date
- 6.6 Global Glucose Dependent Insulinotropic Receptor Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Glucose Dependent Insulinotropic Receptor Market Size (2021-2032)
- 7.2 North America Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Glucose Dependent Insulinotropic Receptor Market Size by Country (2021-2026)
- 7.4 North America Glucose Dependent Insulinotropic Receptor Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Glucose Dependent Insulinotropic Receptor Market Size (2021-2032)
- 8.2 Europe Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Glucose Dependent Insulinotropic Receptor Market Size by Country (2021-2026)
- 8.4 Europe Glucose Dependent Insulinotropic Receptor Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Size (2021-2032)
- 9.2 Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Glucose Dependent Insulinotropic Receptor Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Glucose Dependent Insulinotropic Receptor Market Size (2021-2032)
- 10.2 South America Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Glucose Dependent Insulinotropic Receptor Market Size by Country (2021-2026)
- 10.4 South America Glucose Dependent Insulinotropic Receptor Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Size (2021-2032)
- 11.2 Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Glucose Dependent Insulinotropic Receptor Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda Pharmaceutical Co Ltd
- 12.1.1 Takeda Pharmaceutical Co Ltd Company Information
- 12.1.2 Takeda Pharmaceutical Co Ltd Business Overview
- 12.1.3 Takeda Pharmaceutical Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.1.4 Takeda Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.1.5 Takeda Pharmaceutical Co Ltd Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.2.4 Novartis AG Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Merck & Co Inc
- 12.3.1 Merck & Co Inc Company Information
- 12.3.2 Merck & Co Inc Business Overview
- 12.3.3 Merck & Co Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.3.4 Merck & Co Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.3.5 Merck & Co Inc Recent Developments
- 12.4 GlaxoSmithKline Plc
- 12.4.1 GlaxoSmithKline Plc Company Information
- 12.4.2 GlaxoSmithKline Plc Business Overview
- 12.4.3 GlaxoSmithKline Plc Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.4.4 GlaxoSmithKline Plc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.4.5 GlaxoSmithKline Plc Recent Developments
- 12.5 Amgen Inc
- 12.5.1 Amgen Inc Company Information
- 12.5.2 Amgen Inc Business Overview
- 12.5.3 Amgen Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.5.4 Amgen Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.5.5 Amgen Inc Recent Developments
- 12.6 Yuhan Corp
- 12.6.1 Yuhan Corp Company Information
- 12.6.2 Yuhan Corp Business Overview
- 12.6.3 Yuhan Corp Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.6.4 Yuhan Corp Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.6.5 Yuhan Corp Recent Developments
- 12.7 Taisho Pharmaceutical Holdings Co Ltd
- 12.7.1 Taisho Pharmaceutical Holdings Co Ltd Company Information
- 12.7.2 Taisho Pharmaceutical Holdings Co Ltd Business Overview
- 12.7.3 Taisho Pharmaceutical Holdings Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.7.4 Taisho Pharmaceutical Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.7.5 Taisho Pharmaceutical Holdings Co Ltd Recent Developments
- 12.8 Kowa Co Ltd
- 12.8.1 Kowa Co Ltd Company Information
- 12.8.2 Kowa Co Ltd Business Overview
- 12.8.3 Kowa Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.8.4 Kowa Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.8.5 Kowa Co Ltd Recent Developments
- 12.9 Hyundai Pharmaceutical Co Ltd
- 12.9.1 Hyundai Pharmaceutical Co Ltd Company Information
- 12.9.2 Hyundai Pharmaceutical Co Ltd Business Overview
- 12.9.3 Hyundai Pharmaceutical Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.9.4 Hyundai Pharmaceutical Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.9.5 Hyundai Pharmaceutical Co Ltd Recent Developments
- 12.10 F. Hoffmann-La Roche Ltd
- 12.10.1 F. Hoffmann-La Roche Ltd Company Information
- 12.10.2 F. Hoffmann-La Roche Ltd Business Overview
- 12.10.3 F. Hoffmann-La Roche Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.10.4 F. Hoffmann-La Roche Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.10.5 F. Hoffmann-La Roche Ltd Recent Developments
- 12.11 Dong-A Socio Holdings Co Ltd
- 12.11.1 Dong-A Socio Holdings Co Ltd Company Information
- 12.11.2 Dong-A Socio Holdings Co Ltd Business Overview
- 12.11.3 Dong-A Socio Holdings Co Ltd Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.11.4 Dong-A Socio Holdings Co Ltd Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.11.5 Dong-A Socio Holdings Co Ltd Recent Developments
- 12.12 CymaBay Therapeutics Inc
- 12.12.1 CymaBay Therapeutics Inc Company Information
- 12.12.2 CymaBay Therapeutics Inc Business Overview
- 12.12.3 CymaBay Therapeutics Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.12.4 CymaBay Therapeutics Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.12.5 CymaBay Therapeutics Inc Recent Developments
- 12.13 Arena Pharmaceuticals Inc
- 12.13.1 Arena Pharmaceuticals Inc Company Information
- 12.13.2 Arena Pharmaceuticals Inc Business Overview
- 12.13.3 Arena Pharmaceuticals Inc Revenue in Glucose Dependent Insulinotropic Receptor Business (2021-2026)
- 12.13.4 Arena Pharmaceuticals Inc Glucose Dependent Insulinotropic Receptor Product Portfolio
- 12.13.5 Arena Pharmaceuticals Inc Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst